Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia.
Lisa A
LA
Raedler
N Engl J Med. 2014 Jul 17;371(3):203-12
25014686
JAMA. 2004 Sep 15;292(11):1307-16
15337732
N Engl J Med. 2012 Nov 29;367(22):2089-99
23126252
Nature. 2013 Apr 11;496(7444):152-5
23579660
N Engl J Med. 2005 Apr 7;352(14):1425-35
15755765
Lancet. 1994 Nov 19;344(8934):1383-9
7968073
J Lipid Res. 2009 Apr;50 Suppl:S172-7
19020338
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
24239923
N Engl J Med. 2011 Dec 15;365(24):2255-67
22085343
JAMA. 2005 Nov 16;294(19):2437-45
16287954
N Engl J Med. 2015 Apr 16;372(16):1489-99
25773378
J Am Coll Cardiol. 2006 Aug 1;48(3):438-45
16875966
Circulation. 2002 Oct 8;106(15):1943-8
12370217
N Engl J Med. 2015 Jun 18;372(25):2387-97
26039521
Lancet. 2010 Nov 13;376(9753):1670-81
21067804
N Engl J Med. 2004 Apr 8;350(15):1495-504
15007110